Piramal Pharma Ltd Strategic moves and CDMO business

Management commentary and press material emphasise continued investments in cost optimisation and operational excellence to stabilise margins while targeting more integrated CDMO projects and higher‑value complex offerings, with a long‑term goal of scaling CDMO revenues meaningfully by FY2030. Piramal Pharma is also investing around USD 90 million to expand two US sites and has partnered with NewAmsterdam Pharma to enhance oral solid dosage capabilities at its Sellersville, Pennsylvania site, reinforcing its positioning as a global CDMO.